Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $19 to $15.
Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $19 to $15.